The estimated Net Worth of Christopher L. Carpenter is at least 6.88 千$ dollars as of 16 December 2019. Christopher Carpenter owns over 48,000 units of Rubius Therapeutics Inc stock worth over 6,876$ and over the last 6 years Christopher sold RUBY stock worth over 0$.
Christopher has made over 6 trades of the Rubius Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Christopher exercised 48,000 units of RUBY stock worth 137,760$ on 16 December 2019.
The largest trade Christopher's ever made was exercising 48,000 units of Rubius Therapeutics Inc stock on 16 December 2019 worth over 137,760$. On average, Christopher trades about 32,406 units every 47 days since 2019. As of 16 December 2019 Christopher still owns at least 82,843 units of Rubius Therapeutics Inc stock.
You can see the complete history of Christopher Carpenter stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over 2,165,279$ worth of Rubius Therapeutics Inc stock and bought 305,000 units worth 6,624,680$ . The most active insiders traders include Noubar Afeyan、Roger Pomerantz、Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of 2,709$. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth 1,350$.
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include: